Pfizer making Vaccine which can be protected in Normal Fridge for India
The US company requires a temperature of minus 70 degrees to protect its vaccine, while cold storage facilities with such low temperatures are not available in India.
New Delhi: It is good news for India that US drug maker Pfizer is making a new version of its Corona vaccine to be kept in a simple freeze. Pfizer has begun vaccination by completing a trial of the Corona vaccine in the UK.
Vaccine protection in normal fridge:
They are now exploring possibilities in India. She has applied to the regulatory body for emergency approval in India. The US company requires a temperature of minus 70 degrees to protect its vaccine, while cold storage facilities with such low temperatures are not available in India.
To overcome this problem, the company is preparing a new version of the vaccine.
ALSO READ: Covid-19 vaccines may get license in coming weeks, says health ministry
Pfizer CEO Albert Borla said, 'We are working on a new formulation. Which will not need to be stored at minus 70 degrees. It can be stored under normal refrigeration. ' Meanwhile, the Canadian health regulator has also approved the use of Pfizer vaccines.
Serum and Bharat BioNtech:
Pfizer, Serum Institute of India and Bharat Biotech's application to approve emergency use of their vaccine was discussed by the expert committee of CDSCO on Wednesday. Pfizer has asked for more time for the presentation.
ALSO READ: Corona Updates: India’s recovery rate stands at 94.7 per cent
At the same time, Serum and Bharat Biotech have been asked to provide some more data. The committee has asked Serum to present the updated data for the second and third phase trials. Data from Phase II and Phase III trials have also been sought from Bharat Biotech, which is making indigenous covicin.
ALSO READ: British Old lady Margaret Keenan is 1st in world to get Pfizer Vaccine
Stay tuned with the newstrack to get fastest updates. Click @englishnewstrack to follow us on Facebook and @newstrackmedia to follow on Twitter.